2012 Annual Meeting Abstract Supplement Late-Breaking Abstract Submissions All Late-Breaking Abstracts will be presented on Thursday, March 15, from 8:30 am–12:00 noon. These abstracts will be available via the mobile app and the online Itinerary Planner until April 30, 2012. 51st Annual Meeting and ToxExpo™ San Francisco, California March 11–15, 2012 www.toxicology.org Thursday, March 15, Poster Session, By Location SESSION TITLE ABSTRACT NUMBERS POSTER BOARD #s Carcinogenesis 2657‐2702 101‐146 Late‐Breaking Poster Session 1 Alternatives to Mammalian Models 2738‐2741 147‐150 Animal Models 2742‐2747 151‐156 Autoimmunity 2748‐2749 157‐158 Immunotoxicity 2750‐2755 159‐164 Biomarkers 2756‐2760 165‐169 Exposure Assessment/Biomonitoring 2761‐2765 170‐174 Biological Modeling 2766 175 Oxidative Injury and Redox Biology 2767‐2770 176‐178 and 201 Late‐Breaking Poster Session 2 Disposition/Pharmacokinetics 2771‐2772 202‐203 Pharmacogenomics/Genetic Polymorphisms 2773‐2774 204‐205 Developmental Toxicology 2775‐2780 206‐211 Reproductive Toxicology 2781‐2784 212‐215 Gene Regulation 2785 216 Genotoxicity/DNA Repair 2786‐2794 217‐225 Metals 2795‐2807 226‐238 Mixtures 2808‐2809 239‐240 Risk Assessment 2810‐2817 241‐248 Receptors 2818‐2819 249‐250 Late‐Breaking Poster Session 3 Carcinogenesis 2820‐2825 301‐306 Nanotoxicology 2826‐2842 307‐323 Children's Health/Juvenile Toxicity 2843‐2844 325 and 328 Transcript 'Omics 2845‐2846 326‐327 Ecotoxicology 2847‐2849 329‐331 Natural Products 2850‐2852 332‐334 Food Safety/Nutrition 2853‐2858 335‐340 Neurotoxicity, Developmental 2859‐2860 341‐342 Neurotoxicity, Metals 2861‐2862 343‐344 Neurotoxicity, Pesticides 2863‐2865 345‐347 Neurodegenerative Disease 2866‐2870 348‐352 Late‐Breaking Poster Session 4 Cardiovascular Toxicology/Hemodynamics 2871‐2876 401‐406 Inhalants & Cardiopulmonary 2877‐2880 407‐410 Chemical & Biological Weapons 2881‐2883 411‐413 Regulation/Policy 2884‐2885 414‐415 Stem Cell Biology and Toxicology 2886‐2890 416‐420 Safety Assessment: Non‐Pharmaceutical 2891‐2895 421‐425 Safety Assessment: Pharmaceutical 2896‐2902 426‐432 Pharmaceuticals 2903‐2905 433‐435 Computational Toxicology 2906‐2908 437‐439 Cell Death/Apoptosis 2909‐2911 441‐443 Endocrine Toxicology 2912‐2917 444‐449 Late‐Breaking Poster Session 5 Inflammation and Disease 2918 PS1 Epigenetics 2919‐2920 PS2‐PS3 Epidemiology 2921‐2924 PS4‐PS7 Education, Ethical, Legal and Social Issues 2925 PS8 Signal Transduction 2926 PS9 Biotransformation/Cytochrome P450 2927 PS10 Kidney 2928 PS11 Skin 2929 PS12 Liver 2930‐2933 PS13‐PS16 Thursday, March 15, Poster Session, By Topic TOPIC ABSTRACT NUMBERS POSTER BOARD #s SESSION TITLE Alternatives to Mammalian Models 2738‐2741 147‐150 Late‐Breaking Poster Session 1 Animal Models 2742‐2747 151‐156 Late‐Breaking Poster Session 1 Autoimmunity 2748‐2749 157‐158 Late‐Breaking Poster Session 1 Biological Modeling 2766 175 Late‐Breaking Poster Session 1 Biomarkers 2756‐2760 165‐169 Late‐Breaking Poster Session 1 Biotransformation/Cytochrome P450 2927 PS10 Late‐Breaking Poster Session 5 Carcinogenesis 2657‐2702 101‐146 Carcinogenesis Carcinogenesis 2820‐2825 301‐306 Late‐Breaking Poster Session 3 Cardiovascular Toxicology/Hemodynamics 2871‐2876 401‐406 Late‐Breaking Poster Session 4 Cell Death/Apoptosis 2909‐2911 441‐443 Late‐Breaking Poster Session 4 Chemical & Biological Weapons 2881‐2883 411‐413 Late‐Breaking Poster Session 4 Children's Health/Juvenile Toxicity 2843‐2844 325 and 328 Late‐Breaking Poster Session 3 Computational Toxicology 2906‐2908 437‐439 Late‐Breaking Poster Session 4 Developmental Toxicology 2775‐2780 206‐211 Late‐Breaking Poster Session 2 Disposition/Pharmacokinetics 2771‐2772 202‐203 Late‐Breaking Poster Session 2 Ecotoxicology 2847‐2849 329‐331 Late‐Breaking Poster Session 3 Education, Ethical, Legal and Social Issues 2925 PS8 Late‐Breaking Poster Session 5 Endocrine Toxicology 2912‐2917 444‐449 Late‐Breaking Poster Session 4 Epidemiology 2921‐2924 PS4‐PS7 Late‐Breaking Poster Session 5 Epigenetics 2919‐2920 PS2‐PS3 Late‐Breaking Poster Session 5 Exposure Assessment/Biomonitoring 2761‐2765 170‐174 Late‐Breaking Poster Session 1 Food Safety/Nutrition 2853‐2858 335‐340 Late‐Breaking Poster Session 3 Gene Regulation 2785 216 Late‐Breaking Poster Session 2 Genotoxicity/DNA Repair 2786‐2794 217‐225 Late‐Breaking Poster Session 2 Immunotoxicity 2750‐2755 159‐164 Late‐Breaking Poster Session 1 Inflammation and Disease 2918 PS1 Late‐Breaking Poster Session 5 Inhalants & Cardiopulmonary 2877‐2880 407‐410 Late‐Breaking Poster Session 4 Kidney 2928 PS11 Late‐Breaking Poster Session 5 Liver 2930‐2933 PS13‐PS16 Late‐Breaking Poster Session 5 Metals 2795‐2807 226‐238 Late‐Breaking Poster Session 2 Mixtures 2808‐2809 239‐240 Late‐Breaking Poster Session 2 Nanotoxicology 2826‐2842 307‐323 Late‐Breaking Poster Session 3 Natural Products 2850‐2852 332‐334 Late‐Breaking Poster Session 3 Neurodegenerative Disease 2866‐2870 348‐352 Late‐Breaking Poster Session 3 Neurotoxicity, Developmental 2859‐2860 341‐342 Late‐Breaking Poster Session 3 Neurotoxicity, Metals 2861‐2862 343‐344 Late‐Breaking Poster Session 3 Neurotoxicity, Pesticides 2863‐2865 345‐347 Late‐Breaking Poster Session 3 Oxidative Injury and Redox Biology 2767‐2770 176‐178 and 201 Late‐Breaking Poster Session 1 Pharmaceuticals 2903‐2905 433‐435 Late‐Breaking Poster Session 4 Pharmacogenomics/Genetic Polymorphisms 2773‐2774 204‐205 Late‐Breaking Poster Session 2 Receptors 2818‐2819 249‐250 Late‐Breaking Poster Session 2 Regulation/Policy 2884‐2885 414‐415 Late‐Breaking Poster Session 4 Reproductive Toxicology 2781‐2784 212‐215 Late‐Breaking Poster Session 2 Risk Assessment 2810‐2817 241‐248 Late‐Breaking Poster Session 2 Safety Assessment: Non‐Pharmaceutical 2891‐2895 421‐425 Late‐Breaking Poster Session 4 Safety Assessment: Pharmaceutical 2896‐2902 426‐432 Late‐Breaking Poster Session 4 Signal Transduction 2926 PS9 Late‐Breaking Poster Session 5 Skin 2929 PS12 Late‐Breaking Poster Session 5 Stem Cell Biology and Toxicology 2886‐2890 416‐420 Late‐Breaking Poster Session 4 Transcript 'Omics 2845‐2846 326‐327 Late‐Breaking Poster Session 3 2012 Society of Toxicology Annual Meeting Late‐Breaking Abstracts ABSTRACT FINAL ID: 2738 TITLE: APPLYING A HUMAN ARTIFICIAL CHROMOSOME VECTOR TO DEVELOP A HIGH‐SENSITIVE BIOSENSOR CELL AS IN VITRO RISK ASSESSMENT METHOD. AUTHORS (FIRST INITIAL, LAST NAME): T. Nishida1, Y. Yoshimura2, Y. Nakajima3, Y. Ohmiya4, T. Ohbayashi2, N. Tanaka5, M. Oshimura1 INSTITUTIONS (ALL): 1. Chromosome Engineering Research Center, Tottori University, Yonago, Tottori, Japan. 2. Research Center Bioscience and Technology, Tottori University, Yonago, Tottori, Japan. 3. Health Research Institute, AIST, Takamatsu, Kagawa, Japan. 4. Bioproduction Research Institute, AIST, Tsukuba, Ibaraki, Japan. 5. Hatano Research Institute, Food and Drug Safety Center, Hatano, Kanagawa, Japan. KEYWORDS: In Vitro Alternative Method, Stable luciferase reporter cell line ABSTRACT BODY: Human artificial chromosome (HAC) was developed from human chromosome 21, eliminated all of endogenous genes using homologous recombination. HAC has several advantages such as stable episomal maintenance (avoids insertional mutations), the ability to carry large DNA fragments and transfer into optional cell. Since HAC includes a fluorescent gene and loxP site, allow distinguishing the cells containing HAC easily and site‐specific DNA insertion into HAC via Cre/loxP. In this study, we choose IL‐1β, which has important functions in immune system, attempted to establish IL‐1β monitor stable cell line containing large size regulatory element (~100kb) from BAC clone and luciferase genes, and assessed whether our biosensor cell was more useful reporter system from the aspect of the stability of transgene expression and the sensitivity and the range of linear response against stimuli. We inserted luciferase genes into the BAC containing human IL‐1β gene locus using BAC recombineering system, and introduced into HAC via Cre/loxP in CHO cell. The HAC was transferred from CHO to U937 cell (human leukemic monocyte lymphoma cell line), and we established IL‐1β monitor U937, named IL‐1β HAC U937. To assess the biosensor property of IL‐1β HAC U937, we examined the luciferase reporter assay after LPS (100 ng/mL). The activity of luciferase was started to increase significantly 3 h after LPS. To determine limit detectable concentration, cells were treated with low concentration LPS (0.001‐0.1 ng/mL). As a result of luciferase assay, 0.01 ng/mL LPS was enough concentration to detect immune toxicity. Comparing ELISA with IL‐1β HAC U937, our cell had the wide range reactivity and the more highly sensitivity. In the future, we will establish various biosensor cell lines using this platform (HAC vector, BAC clone and luciferase genes). ABSTRACT FINAL ID: 2739 TITLE: INTERNATIONAL WORKSHOP ON ALTERNATIVE METHODS FOR HUMAN AND VETERINARY RABIES VACCINE TESTING AUTHORS (FIRST INITIAL, LAST NAME): R. McFarland1, J. Kulpa‐Eddy2, R. Levis3, D. Gatewood4, M. Halder5, G. Pulle6, H. Kojima7, V. Doelling8, B. Jones8, N. Johnson8, S. Morefield8, D. Allen8, L. Rinckel8, W. Casey9, W. Stokes9 INSTITUTIONS (ALL): 1. US FDA, Rockville, MD, United States. 2. USDA, Riverdale, MD, United States. 3. US FDA, Bethesda, MD, United States. 4. CVB, USDA, Ames, IA, United States. 5. JRC, IHCP, ECVAM, European Commission, Ispra, Italy. 6. Health Canada, Ontario, ON, Canada. 7. JaCVAM, Tokyo, Japan. 8. ILS, Inc, Research Triangle Park, NC, United States. 9. NICEATM/NTP, NIEHS/NIH/DHHS, Research Triangle Park,